IMMUNPROTEASOMINHIBITOREN

European patent · EP3710457 · In force

Register entry

Publication number
EP3710457
Application number
EP18812554
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Nov 14, 2018
Published
Sep 23, 2020
Granted
Aug 3, 2022
Protection ends at the latest
Nov 13, 2038
Next annual fee due
Nov 30, 2026
IPC classes
C07F 5/04 (2006.01)
A61P 9/00 (2006.01)
A61K 31/69 (2006.01)
Priority
US 201762587375 P 16.11.2017
PCT application
PCT/US2018/061132 14.11.2018
PCT publication
WO2019/099576 23.05.2019
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Dec 1, 2025

    Change

    Published in Swissreg on 01.12.2025

  2. Dec 1, 2024

    Change

    Published in Swissreg on 01.12.2024

  3. Dec 1, 2023

    Change

    Published in Swissreg on 01.12.2023

  4. Jun 14, 2023

    Change

    Published in Swissreg on 14.06.2023

  5. Dec 1, 2022

    Change

    Published in Swissreg on 01.12.2022

  6. Aug 3, 2022

    Granted

    Published in Swissreg on 03.08.2022

Parties

Holder

Principia Biopharma Inc.

220 East Grand Avenue, South San Francisco, CA 94080, US

Inventor

LOU, Yan

South San Francisco, CA 94080, US

BRAMELD, Kenneth Albert

South San Francisco, CA 94080, US

OWENS, Timothy Duncan

South San Francisco, CA 94080, US

GOLDSTEIN, David Michael

South San Francisco, CA 94080, US

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.